March 2, 2010
Lux Biosciences Receives Acceptance of Luveniq™ MAA Filing from European Medicines Agency  

February 4, 2010
Lux Biosciences Files for LUVENIQ™ Approval in US and Europe for Noninfectious Uveitis

November 16, 2009
Lux Biosciences to Present at Lazard Capital Markets 6th Annual Healthcare Conference

October 26, 2009
Potential of Lux Biosciences’ LUVENIQ (LX211) as First Disease Modifying Treatment for Sight-Threatening Non-Infectious Uveitis Highlighted at American Academy of Ophthalmology

October 20, 2009
Lux Biosciences Announces Multiple Presentations on LX211 at Upcoming American Academy of Ophthalmology and American Uveitis Society Annual Meetings

October 19, 2009
Lux Biosciences Completes $50 Million Series B Financing

September 23, 2009
Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye

September 8, 2009
Lux Biosciences to Present at the Thomas Weisel Partners Health Care Conference

May 26, 2009
Lux Biosciences’ Luveniq™ (LX211) Highlighted at International Conference on Ocular Inflammation

May 4, 2009
First Oral Drug for Uveitis Reduces Both Inflammation and Recurrence Rate in Potentially Blinding Eye Disease, Reports Lux Biosciences

March 26, 2009
Lux Biosciences Reports Positive Results from LUMINATE
Phase 3 Program of LX211 (LUVENIQ™) in Uveitis

March 18, 2009
Lux Biosciences Completes Patient Enrollment in LUCIDA Phase 3 Program for Prevention of Corneal Transplant Rejection

February 17, 2009
Lux Biosciences Initiates Phase 1 Study of LX214, a Development Candidate for Dry Eye Syndrome

November 26, 2008
Lux Biosciences Announces European Medicines Agency Acceptance
of Its Pediatric Investigation Plan for LUVENIQ™

November 11, 2008
Lux Biosciences to Present at Lazard Capital Markets 5th Annual Healthcare Conference

September 11, 2008
Lux Biosciences’ Investigational Therapy for Uveitis, Luveniq™,
to be Featured at 7th International Symposium on Uveitis

August 12, 2008
Lux Biosciences Names Paul Chaney, Former President (OSI) Eyetech
and EVP OSI Pharmaceuticals, to Board of Directors

July 31, 2008
Lux Biosciences Presents Preclinical Data Demonstrating Potential of LX214
as Best-in-Class Topical Treatment for Chronic Inflammatory Diseases of the Eye

June 25, 2008
Lux Biosciences Completes Enrollment in LUMINATE Pivotal Trial
Program for Novel Uveitis Therapy, LUVENIQ™

June 19, 2008
Lux Biosciences Names Brett Skolnik Chief Financial Officer

June 18, 2008
Lux Biosciences to Present at Jefferies 2nd Annual Healthcare Conference

April 28, 2008

Lux Biosciences’ Presentations at ARVO Highlight Both Topical and Polymer
Delivery Technologies Targeting Chronic Inflammatory Ocular Diseases

April 24, 2008

Lux Biosciences Reports on Pivotal Programs in Uveitis
and Corneal Transplant Rejection at ARVO Meeting

February 26, 2008
Lux Biosciences to Provide Update on Four Pipeline Programs,
Including Two Phase 3 Clinical Programs, at ARVO 

February 4, 2008

Lux Biosciences to Present at BIO CEO & Investor Conference 2008

January 30, 2008

Lux Granted Fast Track Designation For LX201 For Corneal Transplant Rejection

November 20, 2007

Lux Biosciences to Present at Upcoming Investor Conferences

October 29, 2007

Lux Biosciences To Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference

September 26, 2007

Lux Biosciences Sponsors October 6 Event to Raise Awareness and
Help Fund Research Against Serious Ophthalmic Diseases 

September 17, 2007
Lux Biosciences to Present at 2007 UBS Global Life Sciences Conference

August 30, 2007
Novel Steroid Sparing Strategies for the Treatment of Uveitis and Prevention of Corneal Transplant Rejection to be Subject of International Symposium Sponsored by Lux Biosciences

August 7, 2007
Lux Granted Fast Track Designation by FDA for LX211 for The Treatment of Uveitis 

July 31, 2007
EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal
Product Designation for Lux Biosciences’ LX 211 for The Treatment of Uveitis

June 20, 2007
Lux Biosciences to Present at Jefferies Healthcare Conference

May 22, 2007
Lux Biosciences Expands Biomaterials Technology License from Rutgers University for Controlled Ocular Delivery of Pharmaceuticals

May 4, 2007
Lux Biosciences’ Investigational Therapy for Uveitis, LX211,
is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007

April 4, 2007
Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage Program

March 8, 2007
Lux Biosciences to Present at Cowen & Company 27th Annual Health Care Conference

February 20, 2007
Lux Biosciences Initiates LUMINATE Pivotal Clinical Trials of Its Next-Generation Calcineurin Inhibitor,
LX211, in Uveitis

January 15, 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA For Two Ophthalmic Products

November 28, 2006
Lux Biosciences Receives FDA Clearance for LX211 IND

November 7, 2006
Lux Biosciences Announces Exclusive Worldwide License Agreement with NIH for Late Stage Ophthalmic Product

September 18, 2006
Lux Biosciences Establishes European-Based Operations

September 13, 2006
Lux Biosciences Gains Exclusive Worldwide License
for Polyarylate Patent Estate from Rutgers University
for Ophthalmic Use

July 19, 2006
Lux Biosciences Increases Its Series A Venture Financing
by $13 Million, Bringing the Total Round to $49
Million; Dr. David Schnell of Prospect Venture Partners
Joins Lux Biosciences' Board

July 11, 2006
Lux Biosciences Appoints to Board of Directors David Guyer, SVLS Venture Partner and Former CEO of Eyetech

May 25, 2006 (2)
Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights To ISA247

May 25, 2006 (1)
Lux Biosciences Raises $36 Million in Series A Financing and
Signs Agreement for Advanced Clinical Stage Product